The burgeoning popularity of semaglutide , initially for metabolic conditions, is creating significant attention within the UK , prompting a notable shift in hormone trends. Availability these treatments remains a complex challenge , with public healthcare system coverage currently limited and independent providers offering prescriptions at a premi